Theriva Biologics (TOVX) Fundamental Analysis: Revenue, Earnings & Valuation

6.32 / 10

Outperform

Fundamental analysis rates TOVX as Outperform with a 6.3/10 health score. Strengths include low current‑liabilities ratio, strong interest coverage, high inventory turnover, robust revenue growth and favorable Revenue‑MV/Asset‑MV differentials. Weak points are a modest long‑term debt‑to‑working‑capital ratio and negative PB‑ROE.

Analysis Checks(8/10)

Revenue-MV

Value-0.20

Score3/3

Weight31.10%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value292.23

Score2/3

Weight0.43%

1M Return0.13%

Inventory turnover ratio

Value37.77

Score2/3

Weight-3.55%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value49.17

Score2/3

Weight1.20%

1M Return0.36%

PB-ROE

Value-0.96

Score1/3

Weight25.13%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value5.45

Score1/3

Weight-2.09%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value27.69

Score2/3

Weight-3.61%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value389.68

Score2/3

Weight0.17%

1M Return0.05%

Cost of sales ratio (%)

Value73.08

Score2/3

Weight-3.41%

1M Return-1.13%

Asset-MV

Value0.04

Score3/3

Weight54.61%

1M Return11.61%

Is TOVX fundamentally strong?

TOVX scores 6.32/10 on fundamentals and holds a Discounted valuation at present. Backed by its -146.58% ROE, 0.00% net margin, -0.42 P/E ratio, 0.69 P/B ratio, and 89.07% earnings growth, these metrics solidify its Outperform investment rating.